Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (20582)	7/22/2006 2:17:15 PM
From: fred hayes	Respond to of 52153

>Others?< Hi Jon. Nice choices. And how about ELN and SUPG at their new and improved market caps? I have too much ELN already, but I'm thinking of jumping on SUPG. Already have the 2 you mentioned. Any thoughts on SUPG welcomed. I really don't understand why the stock looks so cheap, but there's usually a reason...

To: Robohogs who wrote (20582)	7/22/2006 3:27:39 PM
From: FiloF	Respond to of 52153

Those would be 2 of mine -- I already own them and don't know if I can afford to buy more. I also think ACAD looks interesting, Possibly MNTA, also.

To: Robohogs who wrote (20582)	7/23/2006 6:11:30 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

Hi, this is Biomaven, reporting in from S.A. and using Rick's account for a good reason or sumthin. Should we do a weekend special on everyone's favorite stocks for new buys? This is a well-timed suggestion. It would be grand if this theme were to continue in my absence. I'll look forward to the banter. For me, it's difficult to pick among my 137 biotechs. I've tried to narrow it down to a fave 30, but it's tough. And you want two? You start. I'll give it thought! Best! Biomaven

To: Robohogs who wrote (20582)	7/24/2006 1:59:04 AM
From: tuck	Read Replies (1) \| Respond to of 52153

Hi, this is Biomaven checking in from S.A., using Tuck's account for some arcane reason of connectivity; it was free and I don't know why. Anyhow, I've narrowed it down to two: PBE and BBH. Oh right, they're not really stocks, umm OK . . . To avoid redundancy -- I own ARNA and PDLI, and have added to both recently (also too far into MNTA, and Mom owns some ACAD) -- I'll go with EXEL and IDIX. Neither my Mom or I own those, and they have been beaten up with all the rest. CYTK also looks pretty cheap. Trickle pick is IVGN. But what I actually bought calls in towards the close on Friday? Is it really a biotech anymore, or a pharma . . . AMGN. I own a core position, but that was a near term trade, so maybe doesn't count (been trading AMGN calls a lot lately; I seem to have some feel for it -- though averaging in is sometimes required -- and you can't beat the liquidity (need to unload 80 calls in a minute at one price? AMGN is one of the few "biotechs" in which you can do this). Was there supposed to be a certain holding period for these picks? Cheers, Biomaven

To: Robohogs who wrote (20582)	7/24/2006 11:36:48 AM
From: scaram(o)uche	Respond to of 52153

PDLI, MNTA, REGN..... several stocks mentioned in response to your query are doing great this morning.

To: Robohogs who wrote (20582)	7/29/2006 4:35:15 PM
From: tom pope	Respond to of 52153

Jon - PDLI from Merrill, 7/28 (buy): Gauging data points for sales, royalties and licensing revs PDL reports Aug. 3 and in gauging potential results on the revenue side, NDC data is pointing to in-line product sales, while royalties should meet or beat estimates based on 1Q antibody sales. Licensing is less predictable, although BiogenIDEC is spending in its collaboration with PDL. We are looking for 2Q EPS, ex-options of $0.06, with consensus at $0.09. We like PDL for its three diverse buckets of revenue (products, royalties, and licensing) and we believe the stock has been the “baby thrown out with the bath water” in a weak biotech tape. We reiterate our Buy rating as we believe PDLI is trading at compelling levels. NDC monthly data for products tracking in-line NDC institutional monthly sales data for PDL’s products in 2Q are tracking in-line with our total estimate of $39mn, with Cardene IV modestly ahead of our $28mn estimate and Retavase modestly below our estimate of $6mn for net sales. Royalties should meet or beat estimates We estimate 2Q royalties at $51mn based on partners’ 1Q antibody sales that collectively totaled about $1.8bn. Results will reflect the seasonally strong 1Q sales of MEDI’s Synagis. Licensing revenue less predictable but BIIB is spending PDL’s licensing revenue comes in large part from BiogenIDEC and Roche and are less predictable. BIIB commented on its 2Q call that it expects to spend about $50mn on its collaboration with PDL in ‘06, though we have no specifics on payments in 2Q. We estimate licensing revenue of $13 mn in 2Q and $60mn for ‘06. Guidance is for $55-65 mn in ‘06 with $40mn from BIIB and Roche.